Trial Profile
A Randomised, Placebo Controlled, Double-blind, Dose Escalation, Single Centre Trial to Evaluate the Safety and Immunogenicity of PnuBioVax Administered on Three Occasions 28 Days Apart at Three Dose Levels in Healthy Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal vaccine (Primary)
- Indications Clostridium difficile infections; Pneumonia
- Focus Adverse reactions; First in man
- Sponsors ImmunoBiology
- 10 Nov 2017 Results published in the Vaccine
- 04 Oct 2016 Status changed from active, no longer recruiting to completed.
- 30 Aug 2016 Planned End Date changed from 1 May 2016 to 1 Sep 2016.